ABVC BioPharma (NASDAQ:ABVC) Announces Earnings Results, Beats Expectations By $0.37 EPS

ABVC BioPharma (NASDAQ:ABVC) posted its earnings results on Wednesday. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.37, Zacks reports.

ABVC BioPharma Stock Performance

Shares of ABVC BioPharma stock opened at $0.96 on Thursday. The stock has a market cap of $25.49 million, a P/E ratio of -2.40 and a beta of 0.57. The stock’s fifty day moving average is $1.32 and its 200 day moving average is $1.35. ABVC BioPharma has a one year low of $0.88 and a one year high of $3.40.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ABVC. Geode Capital Management LLC lifted its position in shares of ABVC BioPharma by 5.8% during the 2nd quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock valued at $246,000 after buying an additional 6,017 shares in the last quarter. Citadel Advisors LLC bought a new stake in ABVC BioPharma during the 3rd quarter worth approximately $48,000. Finally, Millennium Management LLC purchased a new position in ABVC BioPharma during the third quarter valued at approximately $60,000. Institutional investors own 11.38% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, ABVC BioPharma presently has an average rating of “Sell”.

ABVC BioPharma Company Profile

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.